Caribou Biosciences, Inc.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases through its proprietary CRISPR chRDNA genome-editing technology. The company's website is www.cariboubio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Caribou Biosciences, Inc. does
In the company’s own words
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases through its proprietary CRISPR chRDNA genome-editing technology. The company's website is www.cariboubio.com.
The company focuses on developing allogeneic, or off-the-shelf, chimeric antigen receptor T-cell (CAR-T) therapies manufactured in advance from healthy donor cells. This approach aims to provide broad patient access, rapid treatment initiation, and increased manufacturing scalability compared to autologous CAR-T therapies, which require individual patient cell collection and manufacturing. Caribou's chRDNA technology enables precise multiplex genome editing while maintaining genomic integrity, with significantly lower off-target editing rates compared to first-generation CRISPR systems.
The company is advancing two clinical-stage allogeneic CAR-T cell therapy candidates for hematologic malignancies. Vispacabtagene regedleucel (vispa-cel), an anti-CD19 CAR-T therapy, has been evaluated in the ANTLER phase 1 clinical trial for relapsed or refractory B-cell non-Hodgkin lymphoma. The company announced phase 1 results in November 2025 showing an 82 percent overall response rate and 64 percent complete response rate in a confirmatory cohort of 22 second-line large B-cell lymphoma patients. Vispa-cel has received regenerative medicine advanced therapy designation, fast track designation, and orphan drug designation from the FDA. CB-011, an anti-BCMA CAR-T therapy, is being evaluated in the CaMMouflage phase 1 clinical trial for relapsed or refractory multiple myeloma. The company announced dose escalation results in November 2025 with a recommended dose for expansion of 450 million viable CAR-T cells.
Caribou employs genome-editing strategies including checkpoint disruption through PD-1 knockout and immune cloaking through B2M removal and HLA-E insertion to enhance CAR-T cell activity and persistence. The company owns a robust worldwide patent portfolio protecting its Cas9 and Cas12a chRDNA compositions and genome-editing methods. In April 2025, Caribou announced strategic prioritization efforts focusing resources on vispa-cel and CB-011 while discontinuing its GALLOP trial for lupus and AMpLify trial for acute myeloid leukemia.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BERKELEY, CA
- Fiscal year end
- December
- CIK
- 1619856
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Caribou Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Caribou Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Caribou Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Caribou Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Caribou Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”